- Oops!Something went wrong.Please try again later.
- Updated data on analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes
- Potentially increasing safety and efficacy in Freeline’s AAV delivery model
LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on analytical technologies for determining the proportion of Adeno-associated viruses (AAV) capsids containing full-length vector genomes will be presented at the 12th Annual Protein and Antibody Engineering Summit (PEGS), 9 – 13 November 2020.
Freeline will present updated data on the use of analytical technologies for determining the proportion of AAV capsids containing full-length vector genomes, including the use of a panel of assays and combination of methodologies to fully characterise the AAV product. The ‘full-to-empty’ ratio discussed is an important quality attribute for AAVs with potential impact on safety and efficacy.
“We are pleased to report additional data on analytical technologies,” said Theresa Heggie, CEO of Freeline Therapeutics. “This announcement comes in the final quarter of a pivotal year for Freeline, with a strengthened balance sheet following the successful launch of our IPO, continued progress in our clinical programmes in Haemophilia B and Fabry Disease, as well as advancements in our preclinical programmes in Gaucher Disease and Haemophilia A. It has always been our ambition to produce the best-in-class capsid, and these technologies will allow us to potentially increase safety and efficacy across our platform which will benefit all of our programmes.”
Title: Analytical Technologies for Determining the Proportion of AAV Capsids Containing Full-Length Vector Genomes
Presenter: Sonya Schermann, Director of Analytical Development at Freeline
Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.
This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s strategies, financing plans, and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of an infectious diseases in the U.S., U.K. or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programmes or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
+44 (0) 7818 430877